Apramycin (Nebramycin II), an aminoglycoside antibiotic for animals, is widely used to treat Salmonella, Escherichia coli, and other infections[1]. Apramycin showed potent in-vitro activity against hypervirulent carbapenem-resistant K pneumoniae isolates, including those resistant to amikacin or gentamicin[2].
Apramycin (50mg/L, overnight) was used as a selection marker to successfully select isolates with the restoration of functional wild type Ompk35 or Ompk36[3].
Apramycin (20mg/kg, i.p.) and citrulline combined with glutamine significantly improved the body condition of the infected mice[1]. Apramycin (20, 80, or 500mg/kg, s.c.) demonstrated a dramatic therapeutic effect against A. baumannii strains MSRN7465, MSRN1450 and FDA-CDC278 in neutropenic murine thigh infection model[4].
References:
[1] Yong Y, Zhou Y, Liu K, et al. Exogenous citrulline and glutamine contribute to reverse the resistance of Salmonella to apramycin. Frontiers in Microbiology. 2021 Oct 14;12:759170.
[2] Melchiorri D, Rocke T, Alm RA, et al. Addressing urgent priorities in antibiotic development: insights from WHO 2023 antibacterial clinical pipeline analyses. The Lancet Microbe. 2024 Oct 22.
[3] Sun L, Li H, Wang Q, et al. Increased gene expression and copy number of mutated bla KPC lead to high-level ceftazidime/avibactam resistance in Klebsiella pneumoniae. BMC microbiology. 2021 Dec;21:1-0.
[4] Kang AD, Smith KP, Berg AH, et al. Efficacy of apramycin against multidrug-resistant Acinetobacter baumannii in the murine neutropenic thigh model. Antimicrobial agents and chemotherapy. 2018 Apr;62(4):10-128.
Apramycin (Nebramycin II)是一种动物用氨基糖苷类抗生素,广泛用于治疗沙门氏菌、大肠杆菌和其他感染[1]。Apramycin对高毒力的耐卡巴培南肺炎克雷伯菌分离株(包括对阿米卡星或庆大霉素有耐药性的分离株)表现出强效的体外活性[2]。
Apramycin(50mg/L,过夜)被用作选择标记,成功筛选出恢复功能性野生型Ompk35或Ompk36的分离株[3]。
Apramycin(20mg/kg,腹腔注射)和瓜氨酸与谷氨酰胺联合使用可显著改善受感染小鼠的身体状况[1]。Apramycin(20、80或500mg/kg,皮下注射)在粒细胞减少性小鼠大腿感染模型中对鲍曼不动杆菌菌株MSRN7465、MSRN1450和FDA-CDC278表现出显著的治疗效果[4]。
















